Discovery of novel antituberculosis agents among 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives targeting aminoacyl-tRNA synthetases

Abstract Antibiotic resistance is a major problem of tuberculosis treatment. This provides the stimulus for the search of novel molecular targets and approaches to reduce or forestall resistance emergence in Mycobacterium tuberculosis. Earlier, we discovered a novel small-molecular inhibitor among 3...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mariia Yu. Rybak, Anatoliy O. Balanda, Anna P. Yatsyshyna, Igor. M. Kotey, Sergiy A. Starosyla, Volodymyr G. Bdzhola, Lubov L. Lukash, Sergiy M. Yarmoluk, Michael A. Tukalo, Galyna P. Volynets
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2895faeaf24341efba42a3825c6db018
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2895faeaf24341efba42a3825c6db018
record_format	dspace
spelling	oai:doaj.org-article:2895faeaf24341efba42a3825c6db0182021-12-02T13:27:08ZDiscovery of novel antituberculosis agents among 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives targeting aminoacyl-tRNA synthetases10.1038/s41598-021-86562-y2045-2322https://doaj.org/article/2895faeaf24341efba42a3825c6db0182021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86562-yhttps://doaj.org/toc/2045-2322Abstract Antibiotic resistance is a major problem of tuberculosis treatment. This provides the stimulus for the search of novel molecular targets and approaches to reduce or forestall resistance emergence in Mycobacterium tuberculosis. Earlier, we discovered a novel small-molecular inhibitor among 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazoles targeting simultaneously two enzymes—mycobacterial leucyl-tRNA synthetase (LeuRS) and methionyl-tRNA synthetase (MetRS), which are promising molecular targets for antibiotic development. Unfortunately, the identified inhibitor does not reveal antibacterial activity toward M. tuberculosis. This study aims to develop novel aminoacyl-tRNA synthetase inhibitors among this chemical class with antibacterial activity toward resistant strains of M. tuberculosis. We performed molecular docking of the library of 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives and selected 41 compounds for investigation of their inhibitory activity toward MetRS and LeuRS in aminoacylation assay and antibacterial activity toward M. tuberculosis strains using microdilution assay. In vitro screening resulted in 10 compounds active against MetRS and 3 compounds active against LeuRS. Structure-related relationships (SAR) were established. The antibacterial screening revealed 4 compounds active toward M. tuberculosis mono-resistant strains in the range of concentrations 2–20 mg/L. Among these compounds, only one compound 27 has significant enzyme inhibitory activity toward mycobacterial MetRS (IC50 = 148.5 µM). The MIC for this compound toward M. tuberculosis H37Rv strain is 12.5 µM. This compound is not cytotoxic to human HEK293 and HepG2 cell lines. Therefore, 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives can be used for further chemical optimization and biological research to find non-toxic antituberculosis agents with a novel mechanism of action.Mariia Yu. RybakAnatoliy O. BalandaAnna P. YatsyshynaIgor. M. KoteySergiy A. StarosylaVolodymyr G. BdzholaLubov L. LukashSergiy M. YarmolukMichael A. TukaloGalyna P. VolynetsNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Mariia Yu. Rybak Anatoliy O. Balanda Anna P. Yatsyshyna Igor. M. Kotey Sergiy A. Starosyla Volodymyr G. Bdzhola Lubov L. Lukash Sergiy M. Yarmoluk Michael A. Tukalo Galyna P. Volynets Discovery of novel antituberculosis agents among 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives targeting aminoacyl-tRNA synthetases
description	Abstract Antibiotic resistance is a major problem of tuberculosis treatment. This provides the stimulus for the search of novel molecular targets and approaches to reduce or forestall resistance emergence in Mycobacterium tuberculosis. Earlier, we discovered a novel small-molecular inhibitor among 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazoles targeting simultaneously two enzymes—mycobacterial leucyl-tRNA synthetase (LeuRS) and methionyl-tRNA synthetase (MetRS), which are promising molecular targets for antibiotic development. Unfortunately, the identified inhibitor does not reveal antibacterial activity toward M. tuberculosis. This study aims to develop novel aminoacyl-tRNA synthetase inhibitors among this chemical class with antibacterial activity toward resistant strains of M. tuberculosis. We performed molecular docking of the library of 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives and selected 41 compounds for investigation of their inhibitory activity toward MetRS and LeuRS in aminoacylation assay and antibacterial activity toward M. tuberculosis strains using microdilution assay. In vitro screening resulted in 10 compounds active against MetRS and 3 compounds active against LeuRS. Structure-related relationships (SAR) were established. The antibacterial screening revealed 4 compounds active toward M. tuberculosis mono-resistant strains in the range of concentrations 2–20 mg/L. Among these compounds, only one compound 27 has significant enzyme inhibitory activity toward mycobacterial MetRS (IC50 = 148.5 µM). The MIC for this compound toward M. tuberculosis H37Rv strain is 12.5 µM. This compound is not cytotoxic to human HEK293 and HepG2 cell lines. Therefore, 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives can be used for further chemical optimization and biological research to find non-toxic antituberculosis agents with a novel mechanism of action.
format	article
author	Mariia Yu. Rybak Anatoliy O. Balanda Anna P. Yatsyshyna Igor. M. Kotey Sergiy A. Starosyla Volodymyr G. Bdzhola Lubov L. Lukash Sergiy M. Yarmoluk Michael A. Tukalo Galyna P. Volynets
author_facet	Mariia Yu. Rybak Anatoliy O. Balanda Anna P. Yatsyshyna Igor. M. Kotey Sergiy A. Starosyla Volodymyr G. Bdzhola Lubov L. Lukash Sergiy M. Yarmoluk Michael A. Tukalo Galyna P. Volynets
author_sort	Mariia Yu. Rybak
title	Discovery of novel antituberculosis agents among 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives targeting aminoacyl-tRNA synthetases
title_short	Discovery of novel antituberculosis agents among 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives targeting aminoacyl-tRNA synthetases
title_full	Discovery of novel antituberculosis agents among 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives targeting aminoacyl-tRNA synthetases
title_fullStr	Discovery of novel antituberculosis agents among 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives targeting aminoacyl-tRNA synthetases
title_full_unstemmed	Discovery of novel antituberculosis agents among 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives targeting aminoacyl-tRNA synthetases
title_sort	discovery of novel antituberculosis agents among 3-phenyl-5-(1-phenyl-1h-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives targeting aminoacyl-trna synthetases
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2895faeaf24341efba42a3825c6db018
work_keys_str_mv	AT mariiayurybak discoveryofnovelantituberculosisagentsamong3phenyl51phenyl1h123triazol4yl124oxadiazolederivativestargetingaminoacyltrnasynthetases AT anatoliyobalanda discoveryofnovelantituberculosisagentsamong3phenyl51phenyl1h123triazol4yl124oxadiazolederivativestargetingaminoacyltrnasynthetases AT annapyatsyshyna discoveryofnovelantituberculosisagentsamong3phenyl51phenyl1h123triazol4yl124oxadiazolederivativestargetingaminoacyltrnasynthetases AT igormkotey discoveryofnovelantituberculosisagentsamong3phenyl51phenyl1h123triazol4yl124oxadiazolederivativestargetingaminoacyltrnasynthetases AT sergiyastarosyla discoveryofnovelantituberculosisagentsamong3phenyl51phenyl1h123triazol4yl124oxadiazolederivativestargetingaminoacyltrnasynthetases AT volodymyrgbdzhola discoveryofnovelantituberculosisagentsamong3phenyl51phenyl1h123triazol4yl124oxadiazolederivativestargetingaminoacyltrnasynthetases AT lubovllukash discoveryofnovelantituberculosisagentsamong3phenyl51phenyl1h123triazol4yl124oxadiazolederivativestargetingaminoacyltrnasynthetases AT sergiymyarmoluk discoveryofnovelantituberculosisagentsamong3phenyl51phenyl1h123triazol4yl124oxadiazolederivativestargetingaminoacyltrnasynthetases AT michaelatukalo discoveryofnovelantituberculosisagentsamong3phenyl51phenyl1h123triazol4yl124oxadiazolederivativestargetingaminoacyltrnasynthetases AT galynapvolynets discoveryofnovelantituberculosisagentsamong3phenyl51phenyl1h123triazol4yl124oxadiazolederivativestargetingaminoacyltrnasynthetases
_version_	1718393018975780864

Discovery of novel antituberculosis agents among 3-phenyl-5-(1-phenyl-1H-[1,2,3]triazol-4-yl)-[1,2,4]oxadiazole derivatives targeting aminoacyl-tRNA synthetases

Ejemplares similares